Ocusun is a high-tech innovative ophthalmic company located in Guangzhou, China, specializing in the research and development, production, and sale of innovative drugs. The company boasts proprietary treatments for conditions such as cataracts and glaucoma, and is powered by an elite team of scientists, ophthalmic clinical groups, and an international research and development base. Ocusun is founded and chaired by Dr. Li Hanxiong.
Renowned for its groundbreaking drug developments in the field of ophthalmic medicine, Ocusun captures the spotlight with its extensive and modern international research and development base situated in Guangzhou. Covering an area of 6,000 square meters, the facility profoundly illustrates Ocusun's commitment to scientific research and technological advancement. This expansive research complex is not only equipped with advanced laboratory facilities and research instruments, but it also fosters an ideal setting for interdisciplinary collaboration and the exchange of innovative ideas.
Operating on this international level, Ocusun's research and development team-comprising distinguished scientists and ophthalmic experts-is dedicated to creating advanced treatments for ophthalmic diseases such as cataracts and glaucoma. Working within this spacious and potential-laden base, Ocusun's professionals are at the forefront of ophthalmic drug research, ensuring that the company's products meet the rigorous standards of the global market.
Guided by Dr. Li Hanxiong and Dr. Tang Peng Cho, Ocusun is advancing towards global leadership in ophthalmology with innovative products that meet clinical needs. Dr. Li's strategic vision and Dr. Tang's extensive experience drive the company's R&D direction. Together, they nurture a culture of innovation at Ocusun, aiming to improve vision health worldwide.